FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230447633> ?p ?o ?g. }

• W4230447633 endingPage "1588" @default.
• W4230447633 startingPage "1587" @default.
• W4230447633 abstract "AbstractThis newfound ability to reliably identify biomarkers for malignant astrocytomas means that physicians will have a new minimally invasive method to track the success of the patients treatments.Researchers at Emory University's Winship Cancer Institute have identified a novel biomarker for brain tumors and have uncovered a potential role the marker may play when the tumor spreads or comes back after treatment. The study, Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration, is published in the November, 2006issue of Clinical Cancer Research. The biomarker, a protein known as soluble attractin, is normally absent in the central nervous system (CNS) and is undetectable in cerebral spinal fluid (CSF) -- unless malignant astrocytomas -- the most common form of intracranial tumors -- are present in the CNS. The CSF is a liquid that bathes the brain and acts as a reservoir, which can be sampled for analysis of proteins secreted by CNS tumors. This newfound ability to reliably identify biomarkers for malignant astrocytomas means that physicians will have a new minimally invasive method to track the success of the patient's treatments. These biomarkers, singly or in combination will provide a fingerprint of the disease and be able in the future to better define the disease, predict what kind of treatment to use and allow doctors to monitorhow well the tumor responds to treatment.Using proteomic analyses of the CSF of patients with brain tumors, we have identified for the first time that attractin levels are elevated in patients with high-grade astrocytoma, says Erwin VanMeir, PhD, professor of Neurosurgery and Hematology/Oncology and lead-author of the study. Because few noninvasive methods are available for monitoring CNS malignancies, there is an urgent need to find reliable indicators.Van Meir and his colleagues analyzed 60 cerebrospinal fluid or cyst fluid samples from patients with various CNS diseases using proteomics to examine simultaneously all proteins in biologicalsamples. To validate the studys results, attractin levels in a set of 100 normal and tumoral brain samples also were examined. The researchers found elevated attractin levels in 97 percent ofmalignant astrocytomas, with the highest levels in grade IV tumors. The grade of a tumor reflects the level of abnormality its cells exhibit and how quickly the tumor is likely to grow and spread and isa predictor of patient outcome. Low-grade tumors are slow growing and show little abnormality, whereas high-grade tumors are highly abnormal and grow and spread quickly making treatment more difficult. Patients with highly malignant astrocytomas typically have a life expectancy of about 1 year even after neurosurgery, chemotherapy, and radiation therapy; highlighting the pressing need for more research to develop improved therapies. Equally important, the researchers also found that attractin plays a key role in the motility of the cancer cells, which influences their ability to spread in the brain, a major cause of recurrence ofmalignant astrocytoma. Secreted by the tumors themselves, attractin induces cancer cells to migrate, although the mechanism by which it does this is not known. Knowing that attractin modulates themigration and possibly the recurrence of these tumors makes it a promising target for future therapeutic intervention, says Dr. Van Meir. Our studies suggest that measuring attractin levels inpatients with grades II-IV astrocytoma should be explored further as a potential biomarker for monitoring the growth of these tumors or as a potential new target for therapy.This study, which was conducted in collaboration with the Dana Farber Cancer Institute, was funded by the National Institutes of Health, the Genetics and Molecular Biology Program of Emory University's Graduate Division of Biological and Biomedical Sciences, and the National Science Foundation. The team of researchers from Emory included Van Meir, Fatima W. Khwaja, PhD, Daniel Brat, MD, PhD; and Harvard Medical School's Jonathan Duke-Cohan, PhD." @default.
• W4230447633 created "2022-05-11" @default.
• W4230447633 date "2006-12-31" @default.
• W4230447633 modified "2023-09-25" @default.
• W4230447633 title "Proteomics Identifies Soluble Attractin Elevation in CSF of Patients with Malignant Astrocytoma" @default.
• W4230447633 doi "https://doi.org/10.4161/cbt.5.12.3769" @default.
• W4230447633 hasPublicationYear "2006" @default.
• W4230447633 type Work @default.
• W4230447633 citedByCount "0" @default.
• W4230447633 crossrefType "journal-article" @default.
• W4230447633 hasBestOaLocation W42304476331 @default.
• W4230447633 hasConcept C121608353 @default.
• W4230447633 hasConcept C126322002 @default.
• W4230447633 hasConcept C142724271 @default.
• W4230447633 hasConcept C143998085 @default.
• W4230447633 hasConcept C2778227246 @default.
• W4230447633 hasConcept C2778880634 @default.
• W4230447633 hasConcept C2779130545 @default.
• W4230447633 hasConcept C2779134260 @default.
• W4230447633 hasConcept C2779651940 @default.
• W4230447633 hasConcept C2781197716 @default.
• W4230447633 hasConcept C2908800543 @default.
• W4230447633 hasConcept C42219234 @default.
• W4230447633 hasConcept C502942594 @default.
• W4230447633 hasConcept C529278444 @default.
• W4230447633 hasConcept C55493867 @default.
• W4230447633 hasConcept C60644358 @default.
• W4230447633 hasConcept C71924100 @default.
• W4230447633 hasConcept C86803240 @default.
• W4230447633 hasConceptScore W4230447633C121608353 @default.
• W4230447633 hasConceptScore W4230447633C126322002 @default.
• W4230447633 hasConceptScore W4230447633C142724271 @default.
• W4230447633 hasConceptScore W4230447633C143998085 @default.
• W4230447633 hasConceptScore W4230447633C2778227246 @default.
• W4230447633 hasConceptScore W4230447633C2778880634 @default.
• W4230447633 hasConceptScore W4230447633C2779130545 @default.
• W4230447633 hasConceptScore W4230447633C2779134260 @default.
• W4230447633 hasConceptScore W4230447633C2779651940 @default.
• W4230447633 hasConceptScore W4230447633C2781197716 @default.
• W4230447633 hasConceptScore W4230447633C2908800543 @default.
• W4230447633 hasConceptScore W4230447633C42219234 @default.
• W4230447633 hasConceptScore W4230447633C502942594 @default.
• W4230447633 hasConceptScore W4230447633C529278444 @default.
• W4230447633 hasConceptScore W4230447633C55493867 @default.
• W4230447633 hasConceptScore W4230447633C60644358 @default.
• W4230447633 hasConceptScore W4230447633C71924100 @default.
• W4230447633 hasConceptScore W4230447633C86803240 @default.
• W4230447633 hasIssue "12" @default.
• W4230447633 hasLocation W42304476331 @default.
• W4230447633 hasOpenAccess W4230447633 @default.
• W4230447633 hasPrimaryLocation W42304476331 @default.
• W4230447633 hasRelatedWork W1588664497 @default.
• W4230447633 hasRelatedWork W2016341390 @default.
• W4230447633 hasRelatedWork W2021624190 @default.
• W4230447633 hasRelatedWork W2030959855 @default.
• W4230447633 hasRelatedWork W2055375627 @default.
• W4230447633 hasRelatedWork W2065042263 @default.
• W4230447633 hasRelatedWork W2102834827 @default.
• W4230447633 hasRelatedWork W2785039522 @default.
• W4230447633 hasRelatedWork W3175472653 @default.
• W4230447633 hasRelatedWork W4361950309 @default.
• W4230447633 hasVolume "5" @default.
• W4230447633 isParatext "false" @default.
• W4230447633 isRetracted "false" @default.
• W4230447633 workType "article" @default.